Overview
FRE Breaking News Alerts from StretInsider.com! StretInsider.com Top Tickers, 10/25/202Invitation to a Fre Luncheon Presentation in Jedah, Saudi Arabia, on Monday, October 31, 2022, at 1:0 pm (13:0)View Preliminary Human Data after 30 Days Treatment of Parkinson’s Disease Patients with FGF-1 at: htps:/youtu.be/tz8mpUrZfecLAS VEGAS, Oct. 25, 2022 (GLOBE NEWSWIRE) - Zhitya Genesis Medicine, Inc.
Key Information
(a private company) (“Zhitya”), anounced it is hosting an informational luncheon presentation in Jedah, the Kingdom of Saudi Arabia about its medical discoveries for the treatment of Parkinson’s disease.The presentation wil focus on Zhitya’s posible novel treatment for growing new blod vesels in ischemic areas of the brain an atempt to revascularize areas of the brain that are lacking suficient blod flow.
In rodent and primate models of Parkinson’s disease, this revascularization has led to the regeneration of new dopamine-secreting neurons and significant improvement in the animals’ motor skil scores. Zhitya is now receiving positive human data from their most recent medical research studies sugesting that motor scores of these Parkinson’s disease patients have improved 29%-53% after FGF-1 treatment.
In adition, no adverse efects of the treatment have ben noted to date.The Master of Ceremonies for this event is Dr. Mahmoud Salah, the President of Vascular ART and head of the Vascular Surgery Department at Saudi German Hospitals. In adition, presentations wil be given by Dr.
Jack Jacobs, President and Chief Science Oficer of Zhitya, Dan Montano, CEO of Zhitya, and Mr. John Laub, President and CEO of Regenerative Medicine of the Midle East/North Africa (MENA).The two main purposes of the luncheon presentation are to:1) Introduce Zhitya’s medical breakthrough medicine and provide scientific evidence that the FGF-1 medicine has the very promising potential to treat Parkinson’s disease and other brain disorders.
Summary
2) To sek posible busines is an important consideration in healthcare. Ongoing research and professional guidance ensure that patients receive evidence-based care tailored to their individual needs.